Krishnaiah Y S R, Satyanarayana V, Bhaskar P
Department of Pharmaceutical Sciences, Andhra University, Visakhapatnam 530003, India.
Int J Pharm. 2002 Oct 24;247(1-2):91-102. doi: 10.1016/s0378-5173(02)00401-5.
The aim of the present study was to develop a membrane-moderated transdermal therapeutic system (TTS) of nicardipine hydrochloride using 2%w/w hydroxy propyl cellulose (HPC) gel as a reservoir system containing 4%w/w of limonene as a penetration enhancer. The permeability flux of nicardipine hydrochloride through ethylene vinyl acetate (EVA) copolymer membrane was found to increase with an increase in vinyl acetate (VA) content in the copolymer. The effect of various pressure-sensitive adhesives (MA-31, MA-38 or TACKWHITE A 4MED) on the permeability of nicardipine hydrochloride through EVA membrane 2825 (28% w/w VA) or membrane/skin composite was also studied. The results showed that nicardipine hydrochloride permeability through EVA 2825 membrane coated with TACKWHITE 4A MED/skin composite was higher than that coated with MA-31or MA-38. Thus a new TTS for nicardipine hydrochloride was formulated using EVA 2825 membrane coated with a pressure-sensitive adhesive TACKWHITE 4A MED and 2%w/w HPC gel as reservoir containing 4%w/w of limonene as a penetration enhancer. The bioavailability studies in healthy human volunteers indicated that the TTS of nicardipine hydrochloride, designed in the present study, provided steady state plasma concentration of the drug with minimal fluctuations for 20 h with improved bioavailability in comparison with the immediate release capsule dosage form.
本研究的目的是开发一种膜调节型盐酸尼卡地平透皮治疗系统(TTS),使用2%w/w羟丙基纤维素(HPC)凝胶作为储库系统,其中含有4%w/w柠檬烯作为渗透促进剂。发现盐酸尼卡地平通过乙烯-醋酸乙烯酯(EVA)共聚物膜的渗透通量随共聚物中醋酸乙烯酯(VA)含量的增加而增加。还研究了各种压敏胶粘剂(MA-31、MA-38或TACKWHITE A 4MED)对盐酸尼卡地平通过EVA膜2825(28%w/w VA)或膜/皮肤复合物的渗透性的影响。结果表明,涂有TACKWHITE 4A MED/皮肤复合物的EVA 2825膜对盐酸尼卡地平的渗透性高于涂有MA-31或MA-38的膜。因此,使用涂有压敏胶粘剂TACKWHITE 4A MED的EVA 2825膜和2%w/w HPC凝胶作为储库,其中含有4%w/w柠檬烯作为渗透促进剂,制备了一种新的盐酸尼卡地平TTS。在健康人类志愿者中的生物利用度研究表明,本研究设计的盐酸尼卡地平TTS在20小时内提供了药物的稳态血浆浓度,波动最小,与速释胶囊剂型相比,生物利用度有所提高。